
Join to view full profile
1505 Northside BlvdCumming, GA 30041
Phone+1 770-205-5292
Dr. Fenton is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Moon (Cho) Fenton, MD, is an oncologist based in Cumming, GA. She completed her residency in internal medicine at Wayne State University School of Medicine in 2009 and her fellowship in hematology and medical oncology at UPMC Medical Education in 2012. Dr. Fenton has contributed to several significant publications in the field of oncology. Her work includes studies on neoadjuvant targeted therapy in head and neck cancer, treatment patterns in advanced bladder cancer, and clinical practice guidelines for head and neck cancers as well as colorectal cancers. She has also been involved in clinical trials investigating treatments for lung, breast, colorectal, and head and neck cancers. She has received numerous recognitions for Best Doctors in Memphis, TN and Pittsburgh, PA.
Education & Training
UPMC Medical EducationFellowship, Hematology and Medical Oncology, 2009 - 2012
Wayne State University School of MedicineResidency, Internal Medicine, 2006 - 2009
University of Tennessee Health Science Center College of MedicineClass of 2006
Certifications & Licensure
GA State Medical License 2026 - 2028
PA State Medical License 2009 - 2026
AR State Medical License 2012 - 2021
MS State Medical License 2012 - 2021
TN State Medical License 2012 - 2021
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification MOSAIQ, Elekta - IMPAC Medical Systems, Inc., 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification MOSAIQ, Elekta - IMPAC Medical Systems, Inc., 2013-2014, 2016-2017
Clinical Trials
- LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Start of enrollment: 2013 Jun 28
- Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2013 Oct 14
Publications & Presentations
PubMed
- A phase 1 study of berzosertib (M6620, VX-970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETC...Aarti Bhatia, Zhengjia Chen, Yuji Zhang, Justine Yang Bruce, Susanne Arnold
Cancer. 2026-03-15 - 6 citationsResponse to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit.Marco A Mascarella, Tolani F Olonisakin, Purva Rumde, Varun Vendra, Melonie A Nance
Clinical Cancer Research. 2023-02-16 - 10 citationsDefinitive local therapy to head and neck squamous cell carcinoma with distant metastasis.Steven Borson, Yongli Shuai, Barton F Branstetter, Marci Lee Nilsen, Marion A Hughes
Laryngoscope Investigative Otolaryngology. 2022-06-01
Authored Content
- Patient Characteristics and Costs in Recurrent or Refractory Head and Neck Cancer: Retrospective Analysis of a Community Oncology DatabaseMarch 2018
Press Mentions
Head and Neck Cancers and the HPV ConnectionSeptember 2nd, 2021
Northside Expands Access with New ProvidersAugust 22nd, 2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









